Literature DB >> 3354374

Possible involvement of noradrenergic descending pain-modulating pathways in the mode of antinociceptive action of flupirtine, a novel non-opioid analgesic.

B Nickel1, J Engel, I Szelenyi.   

Abstract

These experimental studies were conducted to obtain information about the antinociceptive action of flupirtine within the central nervous system. Flupirtine dose-dependently increased pain threshold in the electrostimulated pain test in mice. Its antinociceptive activity was attenuated by simultaneous administration of the noradrenergic alpha 1/alpha 2-antagonist yohimbine and alpha 2-antagonist idazoxane. By contrast, the analgesia induced by codeine or morphine was not influenced by alpha 2-adrenergic antagonists at all. A striking resemblance could be observed in the pharmaco-EEG of freely moving rats treated with clonidine and flupirtine, respectively. The present results are consistent with the hypothesis that the noradrenergic descending pain-modulating system might be involved in the antinociceptive mode of action of flupirtine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3354374     DOI: 10.1007/bf01967209

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  10 in total

1.  GRID SHOCK TEST FOR ANALGESIC ASSAY IN MICE.

Authors:  L BLAKE; M L GRAEME; E B SIGG
Journal:  Med Exp Int J Exp Med       Date:  1963

2.  [The pharmacologic effect of flupirtine, a structurally new analgesic].

Authors:  V Jakovlev; R D Sofia; U Achterrath-Tuckermann; A von Schlichtegroll; K Thiemer
Journal:  Arzneimittelforschung       Date:  1985

3.  [Mechanism of action of the analgesic flupirtine].

Authors:  B Nickel; A Herz; V Jakovlev; U Tibes
Journal:  Arzneimittelforschung       Date:  1985

4.  Spinal cord pharmacology of adrenergic agonist-mediated antinociception.

Authors:  S V Reddy; J L Maderdrut; T L Yaksh
Journal:  J Pharmacol Exp Ther       Date:  1980-06       Impact factor: 4.030

5.  Flupirtine--a new centrally acting analgesic with unique chemical structure.

Authors:  J Engel
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

6.  Pharmaco-electroencephalography in the rat as a method for characterization of different types of analgesics.

Authors:  B Nickel; H Zerrahn
Journal:  Postgrad Med J       Date:  1987       Impact factor: 2.401

7.  A new series of potent analgesics: dextro 2:2-diphenyl-3-methyl-4-morpholino-butyrylpyrrolidine and related amides. I. Chemical structure and pharmacological activity.

Authors:  P A JANSSEN; A H JAGENEAU
Journal:  J Pharm Pharmacol       Date:  1957-06       Impact factor: 3.765

8.  Comparison of flupirtine maleate and dihydrocodeine in patients following surgery.

Authors:  R A Moore; R E Bullingham; S Simpson; G O'Sullivan; P J Evans; H J McQuay; J W Lloyd
Journal:  Br J Anaesth       Date:  1983-05       Impact factor: 9.166

9.  [Flupirtine in patients with cancer pain].

Authors:  W Scheef; D Wolf-Gruber
Journal:  Arzneimittelforschung       Date:  1985

10.  Depression by flupirtine, a novel analgesic agent, of motor and sensory responses of the nociceptive system in the rat spinal cord.

Authors:  K H Carlsson; I Jurna
Journal:  Eur J Pharmacol       Date:  1987-11-03       Impact factor: 4.432

  10 in total
  4 in total

1.  Effects of flupirtine on the pain-related evoked potential and the spontaneous EEG.

Authors:  G Kobal; T Hummel
Journal:  Agents Actions       Date:  1988-02

2.  Mode of antinociceptive action of flupirtine in the rat.

Authors:  I Szelenyi; B Nickel; H O Borbe; K Brune
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

Review 3.  Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.

Authors:  H A Friedel; A Fitton
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

4.  Influence of flupirtine, a novel nonopioid analgesic agent on somatosensory evoked potentials in rats.

Authors:  L Nagymajtenyi; B Nickel; I Desi; I Szelenyi
Journal:  Experientia       Date:  1992-10-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.